The drug that has a much lower risk of side effects
but is much cheaper than other existing drugs can be implemented.

• 

  Retinal diseasesRetina diseases encompass a group of diseases that occur due to abnormalities in the retina (including the choroid and vitreous body) within the eye and are broadly divided into AMD (Age-Related Macular Degeneration), DME (Diabetic Macular Edema), etc.

• Selective inhibition of only necessary functionsThe existing drugs for retinal degenerative diseases have various side effects, such as photoreceptor damage, retinal atrophy, conjunctival hemorrhage, increased intraocular pressure, cataracts, etc., so there are strong unmet needs for the development of the alternative drugs. And, our AVI-3207 does not inhibit all functions of VEGF, but rather selectively inhibits only VEGFR-2, which is involved in the angiogenesis formation, making it possible to develop a drug that is much less likely to cause side effects.

  
• 

  Development potential of eye dropsIn addition, AVI-3207 is a substance with a much smaller structure than that of other existing drugs, which not only significantly reduces manufacturing costs, but also has the development potential of eye drops rather than injections.